Avalon GloboCare Corp. Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Key Points:
- Nasdaq Deficiency Notice: Avalon GloboCare Corp. (trading symbol: ALBT, listed on NASDAQ) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- Minimum Bid Price Requirement: The rule stipulates that a company’s common stock must maintain a closing bid price of at least \$1.00 per share for a minimum of 10 consecutive business days.
- Compliance Timeline: Avalon GloboCare has 180 calendar days, until October 12, 2026, to regain compliance. Failure to achieve this by the deadline may result in further actions, including the possibility of an additional 180-day compliance period if certain conditions are met.
- Potential Consequences: If the company does not regain compliance during the allotted periods, Nasdaq may proceed with delisting the company’s common stock. Avalon GloboCare would have the opportunity to appeal such a determination to a Hearings Panel.
- Company Response: Avalon GloboCare intends to monitor its closing bid price and may consider available options, including but not limited to a reverse stock split, to restore compliance with Nasdaq’s minimum bid price rule.
- Corporate Information: The current CFO is Luisa Ingargiola, and the company’s common stock is registered under the trading symbol ALBT on NASDAQ.
Details for Shareholders:
- Price Sensitivity: The receipt of a Nasdaq deficiency notice is a significant event for shareholders, as it signals the risk of delisting, which could negatively impact share value and liquidity.
- Reverse Stock Split: The company has explicitly mentioned the possibility of implementing a reverse stock split if necessary to regain compliance. Reverse splits often affect share price and investor sentiment, and shareholders should monitor further announcements closely.
- Appeal Process: Should the company be notified of delisting, Avalon GloboCare can appeal to a Hearings Panel, but there is no guarantee of a favorable outcome.
- Emerging Growth Company Status: Avalon GloboCare is not classified as an emerging growth company, which may affect certain regulatory requirements and investor expectations.
Additional Information:
- Form 8-K Filing: The company filed a Form 8-K to report this event, highlighting its obligation to keep shareholders informed about material developments.
- Other Regulatory Communications: The filing indicates that there are no written communications, soliciting materials, or pre-commencement tender offers related to this event.
Potential Impact on Share Price
The Nasdaq deficiency notice and the risk of delisting are material developments that could significantly impact the share price of Avalon GloboCare. Investors should be aware that failure to meet the minimum bid price requirement, potential reverse stock split, or actual delisting could result in reduced liquidity, lower market value, and heightened volatility.
Disclaimer:
This article is based on information disclosed in Avalon GloboCare Corp.’s SEC filing and is intended for informational purposes only. It does not constitute investment advice. Investors should do their own research and consult with their financial advisors before making any investment decisions. The situation described is subject to change based on future company actions and market conditions.
View Avalon GloboCare Corp. Historical chart here
